

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (canceled)

22. (currently amended): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide wherein said modified kringle 5 peptide comprises a kringle 5 peptide SEQ ID NO: 8 and a reactive group coupled, optionally via a linking group, to said kringle 5 peptide thereto, said reactive group reacting with an amino group, a hydroxyl group, or a thiol group on a blood component to form a stable covalent bond, wherein said reactive group is a succinimidyl succinimidyl-containing group or a maleimido maleimido-containing group, and wherein said kringle 5 peptide comprises SEQ ID NO: 8.

Claim 23 (canceled)

24. (previously presented): The method of claim 22, wherein said blood component is a blood protein.

25. (currently amended): The method of claim 22, wherein said modified kringle 5 peptide is reactive with a thiol group on a blood protein.

Claims 26-27 (canceled)

28. (currently amended): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide comprising a kringle 5 peptide with a maleimido group coupled, optionally via a linking group, to said kringle 5 peptide, thereto, said maleimido group reacting with a thiol group on human serum albumin to form a stable covalent bond wherein said kringle 5 peptide comprises SEQ ID NO: 8.

Claims 29-32 (canceled)

33. (previously presented): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide of the sequence (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO: 39).

34. (currently amended): A method of preparing a conjugate comprising conjugating using a modified kringle 5 peptide *ex vivo* to a blood component, wherein said modified kringle 5 peptide comprises a kringle 5 peptide wherein said kringle 5 peptide comprises SEQ ID NO: 8 and a maleimido group coupled, optionally via a linking group, to said kringle 5 peptide, wherein said maleimido group reacts with a thiol group on of said a blood component protein to form a covalent bond, for manufacturing an anti-angiogenic medicament, and wherein said kringle 5 peptide comprises SEQ ID NO: 8.

35. (currently amended): A conjugate formed by conjugating comprising a modified kringle 5 peptide covalently bonded to a blood component, wherein where said modified kringle 5 peptide comprises a kringle 5 peptide SEQ ID NO: 8 and a maleimido reactive group coupled, optionally via a linking group, to said kringle 5 peptide, wherein said maleimido group reacts with a thiol group of said blood component to form a covalent bond thereto wherein said reactive group is a succinimidyl-containing or a maleimido-containing group, and wherein said reactive group is covalently bonded to a thiol group on the blood component, and wherein said kringle 5 peptide comprises SEQ ID NO: 8.

36. (previously presented): The conjugate of claim 35, wherein said blood component is a blood protein.

Claims 37-41 (canceled)

42. (currently amended): A composition ~~for providing an anti-angiogenic effect to a patient~~, comprising the a conjugate of claim 35 in association with a pharmaceutically acceptable carrier.

43. (currently amended): A The composition comprising the conjugate of claim 36 42, in association with a pharmaceutically acceptable carrier wherein said blood component is a blood protein.

Claims 44-48 (canceled)

49. (currently amended): A conjugate formed by conjugating comprising a modified kringle 5 peptide ~~covalently bonded~~ to albumin, wherein said modified kringle 5 peptide comprises a kringle 5 peptide SEQ ID NO: 8 and a maleimido group coupled, optionally via a linking group, reactive group coupled to said kringle 5 peptide, wherein said maleimido group reacts with a thiol group of said albumin to form a covalent bond thereto, wherein said reactive group is a maleimido-containing group covalently bonded to a thiol group on the albumin, and wherein said kringle 5 peptide comprises SEQ ID NO: 8.

50. (currently amended): The method of claim 22 wherein said reactive group is a succinimidyl succinimidyl-containing group.

Claims 51-55 (canceled)

56. (previously presented): A composition comprising the conjugate of claim 49 in association with a pharmaceutically acceptable carrier.

57. (new): A composition comprising the conjugate of claim 50 in association with a pharmaceutically acceptable carrier.

58. (new): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient the conjugate of claim 35.

59. (new): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient the conjugate of claim 36.

60. (new): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient the conjugate of claim 49.

61. (new): The method of claim 22, wherein said patient is in need of treatment for an inflammatory disorder.

62. (new): The method of claim 22, wherein said patient is in need of treatment for diabetic retinopathy, ocular neovascularization, restenosis, capillary proliferation in atherosclerotic plaques, or osteoporosis.

63. (new): The method of claim 57, wherein said patient is in need of treatment for a cancer or cancer associated disorder.

64. (new): The method of claim 57, wherein said patient is in need of treatment for an inflammatory disorder.

65. (new): The method of claim 57, wherein said patient is in need of treatment for diabetic retinopathy, ocular neovascularization, restenosis, capillary proliferation in atherosclerotic plaques, or osteoporosis.

66. (new): The method of claim 57, wherein said patient is in need of treatment for a cancer or cancer associated disorder.

67. (new): The method of claim 34, wherein said blood component is a blood protein.

68. (new): The method of claim 67, wherein said blood protein is albumin.